Biotech

Pfizer's 20-valent pneumococcal vaccine hits goal in infants

After four doses, all 20 serotypes met the statistical noninferiority criteria in a study that compared the candidate to Prevnar 13.

Nick Paul Taylor Aug 12, 2022 8:00am

Q2 '22 was weakest quarter for biotech IPOs in more than 5 years

Aug 11, 2022 11:15am

Biotechs cut pipeline prospects to focus on priority programs

Aug 11, 2022 9:43am

With no-go from FDA, Affimed to look elsewhere for AML trial

Aug 11, 2022 8:30am

Bolt cans candidate over toxicity, pauses work to extend runway

Aug 11, 2022 7:50am

Vial adds cancer expert as CRO expands oncology trial offering

Aug 11, 2022 6:00am